Weekly NADAC Price Changes
A weekly executive brief covering the pricing movements that matter most to market strategy and reimbursement planning.
- Published NDCs
- 30,211
- Price increases
- 15,052
- Price decreases
- 13,763
- Unchanged prices
- 1,296
NADAC Update: Biologic Price Relief Offsets Broad-Based Generic Increases
The November 18, 2026 NADAC release reflects a near-balanced market with 15,052 price increases against 13,763 decreases across 30,111 comparable NDCs, though dollar-weighted impact skews toward relief in high-cost specialty categories. The Interleukin-23 Antagonist class posted the largest aggregate price pressure at -$1.5M, driven primarily by risankizumab-rzaa, while AbbVie Inc. recorded the largest manufacturer-level decline (-$837.4K) across 64 products. Partially offsetting this, Risperidone saw a +3.5% average increase across 114 NDCs, contributing $677.1K in added cost, and broad-based Corticosteroid movement (1,102 drugs) remained modest despite its scale.
Key takeaways
- Price activity was nearly even (15,052 increases vs. 13,763 decreases), indicating no dominant market-wide directional trend this week.
- High-impact declines were concentrated in specialty and GLP-1 categories: Interleukin-23 Antagonist (-$1.5M), Opioid Antagonist (-$1.1M), and GLP-1 Receptor Agonist (-$922.3K) led dollar-weighted relief.
- Generic breadth drove notable cost pressure, with Risperidone (+3.5%, 114 NDCs) and broad Corticosteroid movement (1,102 drugs) signaling sustained upward pressure outside specialty tiers.
What to watch
Naloxone Hydrochloride Pricing Shift
A -6.8% average move across 20 NDCs produced a -$986.8K impact, with Padagis Israel Pharmaceuticals products (including a -7.4% NDC-level decline) contributing significantly; payers should monitor formulary cost basis for opioid antagonists.
GLP-1 and Liraglutide Volatility
Liraglutide fell -8.0% across 12 NDCs (-$641.6K), part of a broader -$922.3K decline in the GLP-1 Receptor Agonist class; procurement teams should reassess contract pricing assumptions given continued downward momentum.
Interleukin-23 Antagonist Concentration Risk
Despite covering only 4 drugs, this class drove the largest weighted impact (-$1.5M), led by risankizumab-rzaa (-$739.6K across 2 NDCs) and AbbVie's broader -$837.4K swing; limited breadth means pricing shifts here can materially affect specialty drug budgets.
Largest cost pressure
Largest absolute weekly price increase in the current release
Largest relief
Largest absolute weekly price decline in the current release
Top 10 NDCs by weekly price movement
Up to 10 changed products are shown. Each edition preserves its published price comparison.
| Drug | Manufacturer | NDC | Prev. price | Current price | Change |
|---|---|---|---|---|---|
| UZEDY ER 125 MG/0.35 ML SYRING | Teva Pharmaceuticals USA Inc. | 51759063010 | $9,343.0636 | $9,370.2381 | +0.3% |
| NALOXONE HCL 4 MG NASAL SPRAY | Padagis Israel Pharmaceuticals Ltd | 45802057884 | $16.7653 | $15.5264 | -7.4% |
| TREMFYA 100 MG/ML ONE-PRESS | Janssen Biotech, Inc. | 57894064011 | $14,734.2065 | $14,710.6145 | -0.2% |
| CIMZIA 2X200 MG/ML SYRINGE KIT | UCB, Inc. | 50474071079 | $6,098.0431 | $6,115.8171 | +0.3% |
| SKYRIZI 150 MG/ML SYRINGE | AbbVie Inc. | 00074105001 | $22,924.3662 | $22,847.5245 | -0.3% |
| SKYRIZI 150 MG/ML PEN | AbbVie Inc. | 00074210001 | $22,795.0931 | $22,787.7949 | -0.0320% |
| UZEDY ER 250 MG/0.7 ML SYRINGE | Unknown | 51759096010 | $9,317.5524 | $9,366.4286 | +0.5% |
| GLUCAGON 1 MG EMERGENCY KIT | Amphastar Pharmaceuticals, Inc. | 00548585000 | $134.4583 | $128.1424 | -4.7% |
| INVEGA TRINZA 819 MG/2.63 ML | Janssen Pharmaceuticals Inc. | 50458060901 | $4,000.9760 | $3,993.7910 | -0.2% |
| LIRAGLUTIDE 3-PAK 18 MG/3 ML | Teva Pharmaceuticals USA Inc. | 00480366722 | $29.1873 | $25.4444 | -12.8% |
Drug market summaries
Manufacturer movement
Notes and methodology
How the weekly brief calculations were ranked, aggregated, and preserved for archive consistency.
Publication comparison
Prices are compared between the two CMS publication dates shown above, using weekly history snapshots. An unchanged effective date does not mean a publication is missing. NDCs absent from the previous publication are excluded from change calculations; missing prices are not counted as unchanged.
Top mover ranking
The Top 10 table ranks NDCs by absolute weekly impact: the change in unit price multiplied by dispensing exposure when available. The current release had 28,815 NDCs with a measurable publication-to-publication change.
Segment summaries
Drug markets, manufacturers, and therapeutic classes aggregate the same NDC-level deltas. Average move is the mean percent change, while impact is the summed dollar-weighted effect using dispensing-volume exposure when the volume table is available.
Headline cards and archive stability
In editions with headline cards, most pressured class selects the largest positive class impact, and largest manufacturer swing selects the manufacturer with the largest aggregate absolute impact. Every weekly brief stores a frozen snapshot so archived pages do not drift when live NADAC data changes.
More archived editions
Each edition is permanently archived under its release date.
Week of November 11, 2026
NADAC weekly update: no price changes among comparable NDCs — 2026-11-11
The CMS publication dated 2026-11-11 contains 30,157 priced NDCs in our data. Of the 30,096 NDCs also priced in the 2026-11-04 publication, 0 changed and 30,096 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.
Week of November 4, 2026
NADAC weekly update: no price changes among comparable NDCs — 2026-11-04
The CMS publication dated 2026-11-04 contains 30,102 priced NDCs in our data. Of the 30,102 NDCs also priced in the 2026-10-28 publication, 0 changed and 30,102 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.
Week of October 28, 2026
NADAC weekly update: 3 NDCs changed — 2026-10-28
The CMS publication dated 2026-10-28 contains 30,167 priced NDCs in our data. Of the 30,094 NDCs also priced in the 2026-10-21 publication, 3 changed and 30,091 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.
Explore the broader trend ecosystem
Trends overview
Broader market movement and volatility across the full NADAC dataset.
Manufacturers
Compare suppliers and pricing dispersion across product portfolios.
Drug markets
Review generic alternatives by therapeutic market and current pricing.
Therapeutic classes
See category-level swings by prescribing class and market segment.
Understanding NADAC pricing
A primer on how NADAC works and why weekly movement matters.
Methodology
How the data is normalized and aggregated for public reporting.